Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

John N. Allan; Javier Pinilla-Ibarz; Douglas E. Gladstone; Krish Patel; Jeff P. Sharman; William G. Wierda; Michael Y. Choi; Susan M. O'Brien; Mazyar Shadman; Matthew S. Davids; John M. Pagel; Habte A. Yimer; Renee Ward; Gary Acton; Pietro Taverna; Daniel L. Combs; Judith A. Fox; Richard R. Furman; Jennifer R. Brown

doi:10.3324/haematol.2021.280061

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

John N. Allan
, Javier Pinilla-Ibarz
, Douglas E. Gladstone
, Krish Patel
, Jeff P. Sharman
, William G. Wierda
, Michael Y. Choi
, Susan M. O'Brien
, Mazyar Shadman
, Matthew S. Davids
, John M. Pagel
, Habte A. Yimer
, Renee Ward
, Gary Acton
, Pietro Taverna
, Daniel L. Combs
, Judith A. Fox
, Richard R. Furman
, Jennifer R. Brown

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	984-987
Number of pages	4
Journal	Haematologica
Volume	107
Issue number	4
DOIs	https://doi.org/10.3324/haematol.2021.280061
State	Published - Apr 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2021.280061

Cite this

Allan, J. N., Pinilla-Ibarz, J., Gladstone, D. E., Patel, K., Sharman, J. P., Wierda, W. G., Choi, M. Y., O'Brien, S. M., Shadman, M., Davids, M. S., Pagel, J. M., Yimer, H. A., Ward, R., Acton, G., Taverna, P., Combs, D. L., Fox, J. A., Furman, R. R., & Brown, J. R. (2022). Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica, 107(4), 984-987. https://doi.org/10.3324/haematol.2021.280061

Allan, JN, Pinilla-Ibarz, J, Gladstone, DE, Patel, K, Sharman, JP, Wierda, WG, Choi, MY, O'Brien, SM, Shadman, M, Davids, MS, Pagel, JM, Yimer, HA, Ward, R, Acton, G, Taverna, P, Combs, DL, Fox, JA, Furman, RR & Brown, JR 2022, 'Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies', Haematologica, vol. 107, no. 4, pp. 984-987. https://doi.org/10.3324/haematol.2021.280061

@article{3f50e18e733747edb978973fb24ddf96,

title = "Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies",

author = "Allan, \{John N.\} and Javier Pinilla-Ibarz and Gladstone, \{Douglas E.\} and Krish Patel and Sharman, \{Jeff P.\} and Wierda, \{William G.\} and Choi, \{Michael Y.\} and O'Brien, \{Susan M.\} and Mazyar Shadman and Davids, \{Matthew S.\} and Pagel, \{John M.\} and Yimer, \{Habte A.\} and Renee Ward and Gary Acton and Pietro Taverna and Combs, \{Daniel L.\} and Fox, \{Judith A.\} and Furman, \{Richard R.\} and Brown, \{Jennifer R.\}",

note = "Funding Information: Acknowledgments: medical writing support was provided by Janis Leonoudakis, PhD, and was funded by Sunesis Pharmaceuticals, Inc., San Francisco, CA. Funding: financial support for this study was provided by Sunesis Pharmaceuticals, Inc., South San Francisco, CA. Trial registration: clinicaltrials.gov Identifier: NCT03037645; EU clinical trials register identifier: EudraCT \# 2018-000108-41",

year = "2022",

month = apr,

doi = "10.3324/haematol.2021.280061",

language = "English (US)",

volume = "107",

pages = "984--987",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

TY - JOUR

T1 - Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

AU - Allan, John N.

AU - Pinilla-Ibarz, Javier

AU - Gladstone, Douglas E.

AU - Patel, Krish

AU - Sharman, Jeff P.

AU - Wierda, William G.

AU - Choi, Michael Y.

AU - O'Brien, Susan M.

AU - Shadman, Mazyar

AU - Davids, Matthew S.

AU - Pagel, John M.

AU - Yimer, Habte A.

AU - Ward, Renee

AU - Acton, Gary

AU - Taverna, Pietro

AU - Combs, Daniel L.

AU - Fox, Judith A.

AU - Furman, Richard R.

AU - Brown, Jennifer R.

N1 - Funding Information: Acknowledgments: medical writing support was provided by Janis Leonoudakis, PhD, and was funded by Sunesis Pharmaceuticals, Inc., San Francisco, CA. Funding: financial support for this study was provided by Sunesis Pharmaceuticals, Inc., South San Francisco, CA. Trial registration: clinicaltrials.gov Identifier: NCT03037645; EU clinical trials register identifier: EudraCT # 2018-000108-41

PY - 2022/4

Y1 - 2022/4

UR - https://www.scopus.com/pages/publications/85127883243

UR - https://www.scopus.com/pages/publications/85127883243#tab=citedBy

U2 - 10.3324/haematol.2021.280061

DO - 10.3324/haematol.2021.280061

M3 - Letter

C2 - 34937320

AN - SCOPUS:85127883243

SN - 0390-6078

VL - 107

SP - 984

EP - 987

JO - Haematologica

JF - Haematologica

IS - 4

ER -

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this